Adverse Events in Phase II Gastric and Pancreatic Cancer Clinical Trial

Treatment-related adverse events among participants in the LEAP-005 phase II study of lenvatinib plus pembrolizumab for advanced gastric, biliary tract, or pancreatic cancer. The data is a single table (Table 3) from the study results, authored by Mariano Ponz-Sarvisé and last updated in March 2026.

Use Cases

• Analyze the frequency and types of treatment-related adverse events reported in the LEAP-005 clinical trial.
• Correlate specific adverse event outcomes with patient cohorts having gastric, biliary tract, or pancreatic cancer.
• Benchmark safety profiles of the lenvatinib-pembrolizumab combination against other therapies using the tabulated event data.

Strengths

• Data originates from a defined phase II clinical trial (LEAP-005), providing a clear methodological context.
• Published under a permissive CC BY license, allowing for reuse and analysis.
• Last updated in March 2026, indicating recent availability.

Limitations

• The dataset is very small at 9.5 KB, suggesting limited scope, likely a summary table rather than patient-level data.
• Sample data and column definitions are unavailable, hindering immediate understanding of the data structure.
• Represents a single study's results, limiting generalizability without data from broader trials.

Provenance

Source

figshare

Collection Method

Clinical trial results table from the Phase II LEAP-005 study.

Time Range

null

Freshness

null

Geography

null